Send to

Choose Destination
Indian J Med Paediatr Oncol. 2010 Jan;31(1):8-17. doi: 10.4103/0971-5851.68846.

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?

Author information

Department of Medical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India.


Neoadjuvant chemotherapy (NACT) in breast cancer has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. Many questions are still lurking in the minds of oncologists treating breast cancer. This review analyzes the evidence from metaanlyses, major multiinstitutional prospective trials, retrospective institutional series and systematic reviews in breast cancer to determine the current standards and controversies in NACT. The most effective drugs, their advantages, issues and controversies in delivery as well as the criteria for response are reviewed. A summary of evidence-based consensus is presented and unresolved aspects are discussed.


Breast cancer; neoadjuvant chemotherapy; review

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center